Thursday, March 12, 2026 3/12/2026

Neuroimaging and molecular markers of AD and neurodegenerative disease after concussion

Award Number: R01AG058822
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2019
PERIOD OF PERFORMANCE END DATE: 12/31/2030

Group Awards By:

View Award Description

Neuroimaging and molecular markers of AD and neurodegenerative disease after concussion - PROJECT SUMMARY/ABSTRACT Traumatic Brain Injury (TBI) has emerged as a significant risk factor for Alzheimer's Disease (AD) and related dementias. Epidemiological studies indicate that mild TBI more than doubles the risk for dementia; however, the mechanisms underlying this association remain poorly understood. Given the widespread prevalence of mild TBI, which constitutes the majority of all head injuries, its connection to neurodegenerative diseases represents a significant public health concern. Our work in the previous funding period shows that mild TBI confers risk for adverse AD-related outcomes when combined with additional risk factors such as genetic risk for AD. In this renewal project, we aim to build on these findings by identifying the specific genetic and epigenetic pathways that interact with TBI to exacerbate AD-related outcomes. Several biological pathways are implicated in AD, including the regulation of amyloid-beta (Aβ) formation, tau protein binding, protein-lipid complexes, and immune response activation. These pathways may vary in their interaction with TBI. Therefore, in Aim 1 we will examine polygenic risk scores (PRSs) for each AD-associated pathway to identify those that most significantly interact with TBI in relation to cortical thickness, blood biomarkers, and cognitive function. This will help us pinpoint which biochemical pathways to target following TBI. The goal of Aim 2 is to improve detection of AD pathology biomarkers post-TBI by combining multiple polygenic risk scores to increase the explained variance in AD biomarkers. Finally, in Aim 3, we will explore genetic pathways associated with cognitive resilience, particularly those linked to episodic memory, as indicated by our pilot data. This project is significant because identifying the specific biochemical pathways affected by TBI will enhance our ability to predict early AD pathology in individuals with TBI, facilitating targeted interventions and the identification of candidates for clinical trials. The project is conceptually and technically innovative because it leverages longitudinal and multi-omic data, including genetics, blood-based biomarkers, MRI, and neurocognitive data, from a deeply phenotyped sample of over 1000 war veterans spanning young, middle-aged, and older adulthood. Ultimately, this knowledge has the potential to inform clinical judgements regarding dementia treatments and help resolve long-standing debates regarding the relationship between TBI and development of AD.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $581,198 )
2026	2026	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Aging Research	001	6	12/23/2025	COMPETING CONTINUATION	$581,198
2026	2023	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Aging Research	000	5	12/15/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $581,198

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Aging Research	000	5	12/13/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $387,533 )
2023	2023	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Aging Research	000	5	2/15/2023	NON-COMPETING CONTINUATION	$387,533
														Subtotal = $387,533

Issue Date FY: 2022 ( Subtotal = $387,533 )
2022	2022	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Aging Research	000	4	2/4/2022	NON-COMPETING CONTINUATION	$348,780
2022	2022	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Aging Research	001	4	6/2/2022	NON-COMPETING CONTINUATION	$38,753
														Subtotal = $387,533

Issue Date FY: 2021 ( Subtotal = $495,020 )
2021	2021	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Aging Research	000	3	2/15/2021	NON-COMPETING CONTINUATION	$495,020
														Subtotal = $495,020

Issue Date FY: 2020 ( Subtotal = $390,712 )
2020	2020	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Aging Research	000	2	1/30/2020	NON-COMPETING CONTINUATION	$390,712
														Subtotal = $390,712

Issue Date FY: 2019 ( Subtotal = $419,208 )
2019	2019	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Aging Research	000	1	3/20/2019	NEW	$419,208
														Subtotal = $419,208

Grand Total All Awards = $2,661,204

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Neuroimaging and molecular markers of AD and neurodegenerative disease after concussion

Award Number: R01AG058822

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2019

PERIOD OF PERFORMANCE END DATE: 12/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer